P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment
Year: 2016
Type: article
Source: Journal of Thoracic Oncology
Authors: Roy S. Herbst, Paul Baas, Jose L. Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary Jo Fidler, Veerle Surmont, Gilberto De Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon
Institutions: Yale Cancer Center, Yale University, Smilow Cancer Hospital, The Netherlands Cancer Institute, Clinica Universidad de Navarra, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Seoul National University Hospital, National Cancer Center, Mayo Clinic, CHA University Bundang Medical Center, CHA University, Centre François Baclesse, Samsung Medical Center, Sungkyunkwan University, Hospital de Sant Pau, Rush University Medical Center, Ghent University Hospital, Instituto do Câncer do Estado de São Paulo, Pontificia Universidad Católica de Chile, Merck & Co., Inc., Rahway, NJ, USA (United States), University of California, Los Angeles
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2545723552